Ultomiris Copay Assistance

Cómo funciona la asistencia

Optimizando la experiencia de farmacia especializada de nuestros pacientes con una comodidad de servicio completo sin igual

1. Verifique su cobertura/verificación de beneficios

Nuestro equipo de facturadores expertos encuentra las mejores vías de cobertura que minimizan los costos de bolsillo.
2. Transferir receta a AmeriPharma®

Procesamos su receta trabajando con su farmacia o prescriptor anterior, haciendo que la transición sea rápida y sencilla.
3. Autorización previa

Nuestro equipo de especialistas obtiene la aprobación de sus compañías de seguros en un plazo de 24 a 72 horas.
4. Asistencia para copagos y ayuda financiera

Garantizamos ayuda financiera y reducimos copagos, gastos de bolsillo y deducibles elevados. Hasta la fecha, AmeriPharma® Specialty Care ha obtenido $55 millones en asistencia financiera para nuestros pacientes.
5. Coordinación de la atención de enfermería

AmeriPharma® prioriza su agenda y su entorno hogareño al programar y coordinar una de nuestras enfermeras especializadas para sus infusiones en el hogar.
6. Coordinación de entrega

Los medicamentos se entregan siempre en estricto cumplimiento de los requisitos específicos de envío. Las entregas con cadena de frío al día siguiente y al día siguiente se coordinan según su horario.

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/pharmacist.jpg

What Is Ultomiris?

Ultomiris (generic name: ravulizumab) is a type of medication called monoclonal antibodies, similar to antibodies that our bodies make to protect us when an unwanted substance enters our bodies. In the case of Ultomiris, the antibody is humanized, which means its protein sequences have been modified to increase its similarity to those produced naturally in our bodies, making it safe for human administration.

Serious meningococcal infection risk:

Ultomiris has a US Black Box Warning due to the possibility of causing serious meningococcal infection:

“Life-threatening meningococcal infections/sepsis have occurred in patients treated with Ultomiris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.

Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Ultomiris, unless the risks of delaying Ultomiris therapy outweigh the risk of developing a meningococcal infection.

Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Ultomiris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).”

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/block_image_1.jpg

What is Ultomiris Used For?

Ultomiris is used for the treatment of:

Atypical hemolytic uremic syndrome (aHUS), which is a disease that mainly affects kidney function. There is no specific age group for when this condition may occur. It can cause blood clotting to happen abnormally in the small blood vessels of the kidneys, which in turn could cause serious medical problems if blood flow becomes restricted or blocked.
Myasthenia gravis (MG), which is a chronic autoimmune disorder in which the body’s own antibodies start attacking and destroying the connection that is responsible for communication between nerves and muscles. This results in weakness of the skeletal muscles. Myasthenia gravis generally affects voluntary muscles of the body, mainly those controlling the limbs, mouth, throat, and eyes.
Paroxysmal nocturnal hemoglobinuria (PNH), which is a rare, acquired, life-threatening disease of the blood. The disease is characterized by premature destruction of red blood cells, blood clots, and impaired bone marrow function. PNH is closely related to aplastic anemia.

Copago y asistencia financiera

La farmacia especializada AmeriPharma™ alivia las cargas financieras de los pacientes y sus familias

Un software avanzado localiza fuentes de financiación para conectarlo con programas de fundaciones de alto valor
Uno de nuestros especialistas en asistencia de copagos le ayudará con el proceso de solicitud.
Se le enviarán a usted y a su médico actualizaciones automáticas sobre el estado de la financiación.

https://ameripharmaspecialty.com/wp-content/uploads/2024/05/doctor-patient.jpg

Instrucciones de uso

Ultomiris dosing is based on body weight.

Treatment starts with a loading dose, then after 2 weeks, a maintenance dose is administered and then repeated every 8 weeks (4 weeks in some cases with pediatric patients).

Ultomiris is first diluted, then administered intravenously using a catheter that is inserted into the vein. Infusion is done over 36 minutes to 3.5 hours (depending on the dose to be given and the patient’s body weight). Infusions are followed by a 1-hour monitoring time for any signs or symptoms of an infusion reaction.

Ultomiris is only available through a REMS program due to the increased risk of life-threatening meningococcal infections, which can lead to death. Patients must receive the meningococcal vaccine at least 2 weeks before the first dose if they are not already vaccinated.

Ultomiris Side Effects

Diarrea
Dolor de cabeza
Infección del tracto respiratorio superior
Dolor abdominal
Urinary tract infection
Infusion-related reaction
Mareo
Joint stiffness
Dolor de espalda
Pain in the arms or legs
Fiebre
Antibody development
Infection: meningococcal infection, sepsis
Hyperthermia (an abnormally high body temperature, which needs immediate treatment)
Hypersensitivity/anaphylaxis

Seguros aceptados

Aceptamos Medicare, Medicaid multiestatal, Medi-Cal, Blue Shield y la mayoría de los seguros privados. Llámenos para obtener más información sobre su cobertura.